Biochemical Disease-free Survival Rates Following Definitive Low-dose-rate Prostate Brachytherapy With Dose Escalation To Biologic Target Volumes Identified With Spect/ct Capromab Pendetide

Title

Biochemical Disease-free Survival Rates Following Definitive Low-dose-rate Prostate Brachytherapy With Dose Escalation To Biologic Target Volumes Identified With Spect/ct Capromab Pendetide

Creator

Ellis R J; Zhou H; Kim E Y; Fu P F; Kaminsky D A; Sodee B; Colussi V; Vance W Z; Spirnak J P; Kim C; Resnick M I

Publisher

Brachytherapy

Date

2007
2007-01

Subject

adenocarcinoma; brachytherapy; BTV; cancer; conformal radiation-therapy; dosimetry; external-beam radiation; failure definition; hormonal-therapy; Nuclear Medicine & Medical Imaging; Oncology; ProstaScint; prostascint(r); prostate; Radiology; radiotherapy; recommendations; SPECT/CT; survival

Format

Journal Article or Conference Abstract Publication

Search for Full-text

Users with a NEOMED Library login can search for full-text journal articles at the following url: https://libraryguides.neomed.edu/home

Rights

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

Pages

16-25

Issue

1

Volume

6

Citation

Ellis R J; Zhou H; Kim E Y; Fu P F; Kaminsky D A; Sodee B; Colussi V; Vance W Z; Spirnak J P; Kim C; Resnick M I, “Biochemical Disease-free Survival Rates Following Definitive Low-dose-rate Prostate Brachytherapy With Dose Escalation To Biologic Target Volumes Identified With Spect/ct Capromab Pendetide,” NEOMED Bibliography Database, accessed November 28, 2021, https://neomed.omeka.net/items/show/9428.

Social Bookmarking